Pharma Reviews: Cipla will maintain its EBITDA at 22% in FY22: Kedar Upadhye

Q: You have recently signed a deal with Eli Lilly for the drug Baricitinib. ... it is our and pharma industry's responsibility to launch all the drugs in India ...
Read more: Cipla will maintain its EBITDA at 22% in FY22: Kedar Upadhye